BCMA Research Products

B cell maturation antigen (BCMA), a cell surface protein primarily expressed by mature B cells and antibody-producing plasma cells, is an effective immunotherapy target for treating multiple myeloma and other B cell disorders.

BCMA, also known as TNFRSF17 belonging to the TNF receptor superfamily, binds to APRIL/TNFSF13 and BAFF/TNFSF13B/CD257 and regulates B cell development and survival, as well as maintaining plasma cell populations. BCMA can be cleaved by γ-secretase, resulting in a soluble form of BCMA, which is a potential biomarker for multiple myeloma, as well as being a source of interference for potential therapeutics. Targeting BCMA has become a focal point in the development of immunotherapies, including antibody-drug conjugates (ADCs), bispecific T cell engagers (BiTEs), and chimeric antigen receptor (CAR) T cell therapies, aiming to specifically eliminate pathogenic B cells. These innovative approaches may well improve outcomes for patients with various B cell malignancies or autoimmunity, offering new avenues for more effective and targeted treatments.